Published in Alzheimers Res Ther on September 28, 2011
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24
Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. PLoS Biol (2015) 2.93
Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med (2013) 1.92
Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech (2012) 1.66
The challenge and promise of anti-epileptic therapy development in animal models. Lancet Neurol (2014) 1.53
A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease. Mol Neurodegener (2016) 1.41
Improving basic and translational science by accounting for litter-to-litter variation in animal models. BMC Neurosci (2013) 1.12
Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement (2012) 0.96
Minireview: translational animal models of human menopause: challenges and emerging opportunities. Endocrinology (2012) 0.94
Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. Biochem Pharmacol (2014) 0.89
Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease. Int J Alzheimers Dis (2012) 0.89
Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia (2013) 0.88
Identification of changes in neuronal function as a consequence of aging and tauopathic neurodegeneration using a novel and sensitive magnetic resonance imaging approach. Neurobiol Aging (2017) 0.84
Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors. J Neuroimmune Pharmacol (2014) 0.84
Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic. J Neuroinflammation (2015) 0.83
Characterization of Aldh2 (-/-) mice as an age-related model of cognitive impairment and Alzheimer's disease. Mol Brain (2015) 0.82
Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: in Search of a Relevant Mechanism. Mol Neurobiol (2015) 0.81
MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses. PLoS One (2016) 0.78
Biomarker development for myasthenia gravis. Ann N Y Acad Sci (2012) 0.78
Evaluating Health Span in Preclinical Models of Aging and Disease: Guidelines, Challenges, and Opportunities for Geroscience. J Gerontol A Biol Sci Med Sci (2016) 0.78
BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR. PLoS One (2016) 0.77
Induced Pluripotent Stem Cells Derived from Alzheimer's Disease Patients: The Promise, the Hope and the Path Ahead. J Clin Med (2014) 0.76
The fornix provides multiple biomarkers to characterize circuit disruption in a mouse model of Alzheimer's disease. Neuroimage (2016) 0.75
Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model. J Alzheimers Dis (2016) 0.75
Deficits in hippocampal-dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosis. Hippocampus (2015) 0.75
Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener (2017) 0.75
Increased Electron Paramagnetic Resonance Signal Correlates with Mitochondrial Dysfunction and Oxidative Stress in an Alzheimer's disease Mouse Brain. J Alzheimers Dis (2016) 0.75
Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy. Alzheimers Res Ther (2017) 0.75
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94
Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke (2009) 6.79
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol (2010) 5.58
N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol (2007) 4.63
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem (2001) 4.51
Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron (1997) 4.49
Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler (2008) 4.05
Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem (1999) 3.20
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci (2005) 3.20
Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci (2004) 3.09
Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem (2004) 2.45
Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging (2004) 2.31
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp (2008) 1.80
Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci (2008) 1.64
Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs (2009) 1.56
The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging (2005) 1.53
Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci (2000) 1.50
'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci (2010) 1.47
Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci (2004) 1.46
New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics (2008) 1.44
Animal models of normal aging: relationship between cognitive decline and markers in hippocampal circuitry. Behav Brain Res (1993) 1.41
Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem (2004) 1.40
Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm (Vienna) (2001) 1.32
Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord (2000) 1.30
NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.27
Alzheimer's disease and retinal neurodegeneration. Curr Alzheimer Res (2010) 1.26
Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med (2004) 1.24
FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci (2001) 1.22
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets (2009) 1.20
The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp Gerontol (2005) 1.18
Current progress in beta-amyloid immunotherapy. Curr Opin Immunol (2004) 1.18
Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease. Neuroscience (2009) 1.15
Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One (2008) 1.12
Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis (2005) 1.11
Alcohol-induced retrograde memory impairment in rats: prevention by caffeine. Psychopharmacology (Berl) (2008) 1.10
Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. Neuroscience (2005) 1.10
Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol (2001) 1.08
The aged mouse as a model of cognitive decline with special emphasis on studies in NMRI mice. Behav Brain Res (1993) 1.08
Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother (2009) 1.07
Neurochemistry, neuropathology, and heredity in SAMP8: a mouse model of senescence. Neurochem Res (2009) 0.99
The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J Alzheimers Dis (2008) 0.99
Interrogating rodents regarding their object and spatial memory. Curr Opin Neurobiol (2005) 0.98
Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol Aging (2010) 0.96
Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease. Neurodegener Dis (2009) 0.94
Identification of the oxidative stress proteome in the brain. Free Radic Biol Med (2010) 0.92
Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice. J Pharmacol Exp Ther (2010) 0.89
Aged non-human primates: an animal model of age-associated neurodegenerative disease. Brain Pathol (1991) 0.89
Novel age-dependent learning deficits in a mouse model of Alzheimer's disease: implications for translational research. Neurobiol Aging (2009) 0.89
Implanted cannula-mediated repetitive administration of Abeta25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav Brain Res (2005) 0.89
Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model. Neurobiol Aging (2009) 0.88
Senescence-accelerated mouse (SAM) as an animal model of senile dementia: pharmacological, neurochemical and molecular biological approach. Jpn J Pharmacol (1998) 0.87
The effects of selective cholinergic basal forebrain lesions and aging upon expectancy in the rat. Neurobiol Learn Mem (1997) 0.85
Breeding genetically modified rodents: tips for tracking and troubleshooting reproductive performance. Lab Anim (NY) (2005) 0.84
Age-specific onset of beta-amyloid in beagle brains. Neurobiol Aging (1996) 0.81
The role of the veterinary staff in mouse breeding colony management. Lab Anim (NY) (2005) 0.80
Chronic cerebrovascular ischemia in aged rats: effects on brain metabolic capacity and behavior. Neurobiol Aging (2000) 0.79
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell (2011) 3.28
Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem (2007) 3.13
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci (2003) 2.44
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 2.38
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2005) 2.34
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.24
Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc (2006) 2.12
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci (2008) 2.09
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis (2008) 2.01
Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol (2011) 1.97
Evolution of highly pathogenic H5N1 avian influenza viruses in Vietnam between 2001 and 2007. PLoS One (2008) 1.91
Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol (2002) 1.89
Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol (2006) 1.82
Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci (2006) 1.79
Axonal heparan sulfate proteoglycans regulate the distribution and efficiency of the repellent slit during midline axon guidance. Curr Biol (2004) 1.77
Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci (2003) 1.76
A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med (2011) 1.75
APOE genotype-specific differences in the innate immune response. Neurobiol Aging (2007) 1.75
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis (2004) 1.73
New insights into chimpanzees, tools, and termites from the Congo Basin. Am Nat (2004) 1.71
Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci (2006) 1.69
Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A (2008) 1.66
Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci (2008) 1.64
Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med (2012) 1.62
Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol (2004) 1.58
Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci (2009) 1.54
Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem (2008) 1.54
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther (2009) 1.51
Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci (2010) 1.42
LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation (2010) 1.40
Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol (2011) 1.38
Functional molecular ecological networks. MBio (2010) 1.37
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Spatial correlations of laminar BOLD and CBV responses to rat whisker stimulation with neuronal activity localized by Fos expression. Magn Reson Med (2004) 1.35
A preventive intervention for pregnant women on public assistance at risk for postpartum depression. Am J Psychiatry (2006) 1.34
Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2008) 1.33
Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale (2011) 1.32
Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol (2007) 1.32
Development of hydrocephalus in mice expressing the G(i)-coupled GPCR Ro1 RASSL receptor in astrocytes. J Neurosci (2007) 1.30
Population genetics and linkage analysis of loci within the FCT region of Streptococcus pyogenes. J Bacteriol (2006) 1.28
Dopaminergic modulation of risky decision-making. J Neurosci (2011) 1.27
Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci (2009) 1.27
Good things come to those who wait: attenuated discounting of delayed rewards in aged Fischer 344 rats. Neurobiol Aging (2008) 1.26
The association of multiple interacting genes with specific phenotypes in rice using gene coexpression networks. Plant Physiol (2010) 1.25
Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm (2009) 1.23
Discrete surface Ricci flow. IEEE Trans Vis Comput Graph (2008) 1.23
Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem (2008) 1.22
Hemodynamic and metabolic changes induced by cocaine in anesthetized rat observed with multimodal functional MRI. Psychopharmacology (Berl) (2006) 1.21
Roles of the plasminogen activator streptokinase and the plasminogen-associated M protein in an experimental model for streptococcal impetigo. Microbiology (2002) 1.21
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets (2009) 1.20
A high density consensus genetic map of tetraploid cotton that integrates multiple component maps through molecular marker redundancy check. PLoS One (2012) 1.20
Guide for the use of nitric oxide (NO) donors as probes of the chemistry of NO and related redox species in biological systems. Methods Enzymol (2002) 1.20
Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci (2002) 1.19
Evolution of transcription regulatory genes is linked to niche specialization in the bacterial pathogen Streptococcus pyogenes. J Bacteriol (2005) 1.19
Molecular ecological network analyses. BMC Bioinformatics (2012) 1.19
Effects of aging on the hippocampal formation in a naturally occurring animal model of mild cognitive impairment. Exp Gerontol (2003) 1.18
Role of streptococcal T antigens in superficial skin infection. J Bacteriol (2006) 1.18
Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci (2004) 1.18
Phylogenetic molecular ecological network of soil microbial communities in response to elevated CO2. MBio (2011) 1.18
Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc (2006) 1.18
Deficits across multiple cognitive domains in a subset of aged Fischer 344 rats. Neurobiol Aging (2006) 1.18
Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. Mol Ther (2008) 1.17
Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiol Aging (2013) 1.16
Balancing risk and reward: a rat model of risky decision making. Neuropsychopharmacology (2009) 1.16
Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia (2006) 1.16
Laparoscopic liver resection and the learning curve: a 14-year, single-center experience. Surg Endosc (2014) 1.15
Orthogonal properties of the redox siblings nitroxyl and nitric oxide in the cardiovascular system: a novel redox paradigm. Am J Physiol Heart Circ Physiol (2003) 1.15
Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J Pharmacol Exp Ther (2006) 1.14
Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem (2003) 1.14
Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J Biol Chem (2002) 1.14
Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J Neuroinflammation (2013) 1.13
Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. J Neurochem (2004) 1.13
Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. J Biol Chem (2007) 1.13
Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease. Health Aff (Millwood) (2014) 1.13
Curing epilepsy: progress and future directions. Epilepsy Behav (2009) 1.12
Characterizing cognitive aging of spatial and contextual memory in animal models. Front Aging Neurosci (2012) 1.12
Transient relationships among BOLD, CBV, and CBF changes in rat brain as detected by functional MRI. Magn Reson Med (2002) 1.11
Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection. Eukaryot Cell (2007) 1.11
Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood (2003) 1.11
Long-term behavioral consequences of stress exposure in adolescent versus young adult rats. Behav Brain Res (2012) 1.11
Synthesis and characterization of PEG-PCL-PEG thermosensitive hydrogel. Int J Pharm (2008) 1.11
Perpendicular magnetic anisotropy induced by tetragonal distortion of FeCo alloy films grown on Pd(001). Phys Rev Lett (2006) 1.10
Pyrrolidine dithiocarbamate inhibits translocation of nuclear factor kappa-B in neurons and protects against brain ischaemia with a wide therapeutic time window. J Neurochem (2004) 1.10
Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J (2009) 1.08
Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. J Histochem Cytochem (2004) 1.08
Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys (2007) 1.08
Diagnosis prevention and treatment for PICC-related upper extremity deep vein thrombosis in breast cancer patients. Asia Pac J Clin Oncol (2012) 1.07
A quantitative genotype algorithm reflecting H5N1 Avian influenza niches. Bioinformatics (2007) 1.07
Whole-genome association study on tissue tropism phenotypes in group A Streptococcus. J Bacteriol (2011) 1.06
Apolipoprotein E isoform mediated regulation of nitric oxide release. Free Radic Biol Med (2002) 1.06
Enhanced capillary amyloid angiopathy-associated pathology in Tg-SwDI mice with deleted nitric oxide synthase 2. Stroke (2010) 1.05
The mechanism of gamma-secretase: multiple inhibitor binding sites for transition state analogs and small molecule inhibitors. J Biol Chem (2003) 1.05
Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci U S A (2007) 1.04